Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) Short Interest Up 73.3% in May

Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXSGet Rating) was the recipient of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 5,200 shares, a growth of 73.3% from the April 30th total of 3,000 shares. Based on an average daily trading volume, of 12,900 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Ayala Pharmaceuticals in a research report on Saturday, May 20th. They issued a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of Ayala Pharmaceuticals stock opened at $0.99 on Friday. Ayala Pharmaceuticals has a 1 year low of $0.65 and a 1 year high of $7.20. The company has a market capitalization of $1.80 million, a P/E ratio of -0.11 and a beta of 2.45. The company’s fifty day moving average is $0.99 and its two-hundred day moving average is $1.31.

About Ayala Pharmaceuticals

(Get Rating)

Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.

Featured Articles

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.